Stock 4598 DELTA-FLY PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Delta-Fly Pharma, Inc.

Equities

4598

JP3549370009

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
778 JPY -2.87% Intraday chart for Delta-Fly Pharma, Inc. -2.02% -23.35%
Apr. 08 Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax CI
Mar. 11 Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML CI

Valuation

Fiscal Period: März 2019 2020 2021 2022 2023
Capitalization 1 8,866 3,518 7,340 6,937 6,560
Enterprise Value (EV) 1 5,370 1,580 5,252 5,669 5,716
P/E ratio -11.9 x -2.24 x -7.4 x -7.17 x -4.39 x
Yield - - - - -
Capitalization / Revenue - 35.2 x 24.5 x 23.1 x -
EV / Revenue - 15.8 x 17.5 x 18.9 x -
EV / EBITDA -9,086,156 x -1,023,360 x -6,178,665 x -5,905,091 x -4,350,444 x
EV / FCF -16,993,413 x -1,468,976 x -13,015,776 x -9,848,229 x -7,084,721 x
FCF Yield -0% -0% -0% -0% -0%
Price to Book 2.53 x 1.71 x 3.27 x 5.63 x 8.2 x
Nbr of stocks (in thousands) 4,370 4,505 5,300 5,419 6,369
Reference price 2 2,029 781.0 1,385 1,280 1,030
Announcement Date 6/24/19 6/29/20 6/30/21 6/30/22 6/26/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net sales 1 150 - 100 300 300 -
EBITDA - -591 -1,544 -850 -960 -1,314
EBIT 1 -243 -592 -1,545 -852 -961 -1,315
Operating Margin -162% - -1,545% -284% -320.33% -
Earnings before Tax (EBT) 1 -245 -671 -1,552 -859 -964 -1,325
Net income 1 -246 -673 -1,555 -862 -967 -1,328
Net margin -164% - -1,555% -287.33% -322.33% -
EPS 2 -92.09 -170.0 -348.1 -187.2 -178.5 -234.4
Free Cash Flow - -316 -1,076 -403.5 -575.6 -806.9
FCF margin - - -1,075.62% -134.5% -191.88% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/5/18 6/24/19 6/29/20 6/30/21 6/30/22 6/26/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2021 S1 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3 2024 Q1 2024 S1 2024 Q3
Net sales - 100 100 - - - - - - -
EBITDA - - - - - - - - - -
EBIT 1 -725 -463 -554 -278 -304 -611 -415 -275 -593 -356
Operating Margin - -463% -554% - - - - - - -
Earnings before Tax (EBT) 1 -729 -463 -555 -280 -307 -620 -415 -280 -599 -372
Net income 1 -731 -464 -557 -280 -308 -622 -416 -280 -600 -372
Net margin - -464% -557% - - - - - - -
EPS 2 -165.2 -103.2 -103.0 -51.68 -56.96 -114.9 -75.30 -43.07 -91.92 -50.17
Dividend per Share - - - - - - - - - -
Announcement Date 11/14/19 11/12/20 11/11/21 2/14/22 8/12/22 11/14/22 2/14/23 8/14/23 11/13/23 2/13/24
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 762 3,496 1,938 2,088 1,268 844
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -316 -1,076 -404 -576 -807
ROE (net income / shareholders' equity) -30.9% -31.1% -55.9% -41.7% -58.4% -131%
ROA (Net income/ Total Assets) -16.6% -16.7% -33.7% -24.6% -34.5% -73.7%
Assets 1 1,484 4,030 4,613 3,499 2,805 1,802
Book Value Per Share 2 308.0 803.0 456.0 424.0 227.0 126.0
Cash Flow per Share 2 292.0 804.0 431.0 426.0 234.0 134.0
Capex - 1 13 - - -
Capex / Sales - - 13% - - -
Announcement Date 9/5/18 6/24/19 6/29/20 6/30/21 6/30/22 6/26/23
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
DELTA-FLY PHARMA, INC. Stock Delta-Fly Pharma, Inc.
-23.35% 40.67M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4598 Stock
  4. Financials Delta-Fly Pharma, Inc.